MedTrace Logo

Preventive Effect of Leg Wrapping Combined With Trendelenburg Position on Hypotension Induced by Propofol

NCT03074955 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2017-03-09

No results posted yet for this study

Summary

Although propofol is widely used as an induction agent for a general anesthesia, it can induce a profound hypotension, which leads to the hypo-perfusion of end organs and eventually increases morbidities. Theoretically, applying Trendelenburg position (head down and leg up position) increases cardiac preloads and cardiac outputs. However, in past researches, changing to Trendelenburg position alone is not enough and does not prevent propofol induced hypotension. Previous studies proved that leg wrapping effectively prevent hypotension after neuraxial anesthesia during Cesarean section. The leg wrapping prevents hypotension by increasing vascular resistance of lower extremities. The investigators made a hypothesis that applying both Trendelenburg position and leg wrapping prevent propofol induced hypotension more effectively than either applying Trendelenburg position only or taking no preventive measures.

Conditions

Interventions

DEVICE

leg wrapping with tension

1. Apply elastic bandages with tension to both legs before injecting propofol. 2. After 3 minutes, remove elastic bandages.

PROCEDURE

Trendelenburg position

1. Apply Trendelenburg position positon of 10 degree after injectin propofol 2. After 3 minutes, change to supine position

DEVICE

leg wrapping without tension

1. Apply elastic bandages without tension to both legs before injecting propofol. 2. After 3 minutes, remove elastic bandages

PROCEDURE

supine position

1.maintain supine position

Sponsors & Collaborators

  • Hyungmook Lee

    lead OTHER

Principal Investigators

  • MiHyun Kim, Dr. PhD. · Department of anesthesia and pain medicine, Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-16
Primary Completion
2018-07-31
Completion
2018-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03074955 on ClinicalTrials.gov